Application of transient receptor potential cation channel TRPV3 in development of medicines for preventing or treating psoriasis

A transient receptor potential, cation technology, applied in the field of medicine, can solve the problems of less research on the physiological function of TRPV3, lack of specificity, etc., and achieve the effect of good prevention or treatment, less drug side effects, and high accuracy.

Pending Publication Date: 2019-10-18
JIANGSU CONSORT MEDICAL TECH CO LTD
View PDF4 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to the lack of specific agonists and specific in

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of transient receptor potential cation channel TRPV3 in development of medicines for preventing or treating psoriasis
  • Application of transient receptor potential cation channel TRPV3 in development of medicines for preventing or treating psoriasis
  • Application of transient receptor potential cation channel TRPV3 in development of medicines for preventing or treating psoriasis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] This example is used to illustrate the application of the present invention for screening drugs for the prevention or treatment of psoriasis with TRPV3 as the target.

[0056] (1) Imiquimod-induced mouse psoriasis model

[0057] Sixteen C57BL / 6 mice, half male and half male, weighing 18-20 g, were purchased from the Comparative Medicine Center of Yangzhou University. The back hair of the mouse was shaved, and a 2×1.5 cm modeling area was drawn on the back skin with a marker pen. The mice were randomly divided into 2 groups (8 mice in each group) according to male and female. Before the experiment, the mice were raised in a quiet environment avoiding strong light for 3 days to adapt to the environment. The ratio of light to dark time was 1:1, the room temperature was controlled at 25°C, and the humidity was 55%. The mice could eat and drink freely. 62.5 mg 5% (0.1 g: 2 g) imiquimod ointment (Zhuhai United Laboratories Co., Ltd.) was continuously applied to the back ski...

Embodiment 2

[0073] This example is used to further illustrate the application of the present invention for screening drugs for preventing or treating psoriasis with TRPV3 as a target.

[0074] (1) Culture of human immortalized keratinocyte HaCaT cell line

[0075] The human immortalized keratinocyte HaCaT cell line was purchased from Sebekon Biotechnology Co., Ltd. (Shanghai, China). The culture condition of HaCaT cells is DMEM medium (GIBCO, product number 11965-092) containing 10% FBS (GIBCO, product number 16000-044), in 5% CO 2 , 37°C, and cultivated in an incubator with a humidity of 70%-80%. If the cell density reaches 80%-90%, it can be subcultured. The culture supernatant was discarded, and PBS containing no calcium and magnesium ions (containing 137mM NaCl, 2.7mM KCl, 10mM NaCl 2 HPO 4 , 2mM KH 2 PO 4 , pH=7.4) wash the cells 1-2 times. Add 2mL of digestion solution (0.25% Trypsin-0.53mMEDTA) to the culture flask, place it in a 37°C incubator for 1-2 minutes, and then obse...

Embodiment 3

[0087] This example is used to illustrate the application of the TRPV3 inhibitor provided by the present invention, preferably scutellarein, in the prevention or treatment of psoriasis.

[0088] (1) Acquisition, cultivation and identification of cell lines stably transfected with TRPV3

[0089] The mTRPV3 plasmid was donated by the University of Texas Health Science Center, Professor Michael X.Zhu.

[0090] Transfection steps: HEK293 cells with a confluence of 70-80% and good growth status were inoculated in T-60 small dishes one day before transfection, and each small dish contained 4×10 5 Cells were cultured without double antibody at 37°C in 5% CO 2 Incubate overnight in the environment. The next day, 10 μL of plasmid (plasmid concentration: 1000ng / μL) was diluted into 250 μl of DMEM (DMEM, catalog number: 12800017, Gibco), 10 μL of Lipofectamine 2000 (Lipofectamine 2000, catalog number: 11668027, Gibco) was diluted into 250 μL of DMEM, and 250 μL of Lipofectamine 20 The...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a pathophysiological effect of a Transient Receptor Potential cation channel, subfamily V, member 3 (TRPV3) in psoriasis, which can be used for developing medicines for preventing or treating psoriasis. The invention further discloses application of scutellarein serving as an inhibitor of TRPV3 in preparation of medicines for preventing or treating the psoriasis. A medicinecontaining the TRPV3 inhibitor can achieve an excellent prevention or treatment effect when being used for preventing or treating the psoriasis.

Description

technical field [0001] The present invention relates to the field of medicine, specifically, the application of TRPV3 inhibitors in the prevention or treatment of psoriasis and the related effects of scutellarein as a TRPV3 inhibitor in the treatment of psoriasis and the enhancement of its TRPV3 function / expression. application in disease medicine. Background technique [0002] Psoriasis is a common erythematous, scaly skin inflammatory disease that afflicts 2-3% of the population worldwide. According to clinical features, psoriasis can be divided into vulgaris, joint, pustular and erythrodermic, and more than 90% of psoriasis belong to vulgaris. Psoriasis can appear on multiple parts of the body and is typically characterized by red papules and plaques covered with silvery white scales. Because of its long course of disease, easy recurrence, difficult to cure, and often causes damage to the patient's appearance, it has a greater impact on the patient's physical health and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/00A61K31/352A61P17/06
CPCA61K45/00A61K31/352A61P17/06C12Q1/6883G01N33/6893G01N33/5005C12Q2600/158G01N2800/205
Inventor 曹征宇王雨晶殷志琦
Owner JIANGSU CONSORT MEDICAL TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap